(RTTNews) - Hanmi Pharm. Co., Ltd. (128940.KS), a South Korean biopharmaceutical and manufacturing company, on Tuesday reported a decline in net income despite higher sales in the third quarter of 2026 compared with the previous year.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.